{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:35:09Z","timestamp":1781483709144,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.3816\/clm.2002.s.006","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T01:01:57Z","timestamp":1221181317000},"page":"S29-S34","source":"Crossref","is-referenced-by-count":37,"special_numbering":"S1","title":["Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg\u00ae) Therapy of Acute Myeloid Leukemia"],"prefix":"10.3816","volume":"2","author":[{"given":"Lance H.","family":"Leopold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Feingoldr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2002.s.006_bib1","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.s.006_bib2","first-page":"301a","article-title":"An updated report of the efficacy and safety of gemtuzumab ozogamicin in 188 patients with acute myeloid leukemia in first relapse","volume":"20","author":"Stadtmauer","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.s.006_bib4","first-page":"124a","article-title":"Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin Mylotarg\u00ae, CMA-676)","volume":"98","author":"Stadtmauer","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.006_bib5","first-page":"1126","article-title":"Carboplatin infusion in relapsed and refractory acute myeloid leukemia\u2013a Southwest Oncology Group trial","volume":"9","author":"Welborn","year":"1995","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.s.006_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/oxfordjournals.annonc.a010796","article-title":"Probability of long-term diseasefree survival for acute myeloid leukemia patients after first relapse: a single-centre experience","volume":"7","author":"Vignetti","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.s.006_bib7","first-page":"196","article-title":"Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group","volume":"7","author":"Carella","year":"1993","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.s.006_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.1989.7.1.45","article-title":"Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine","volume":"7","author":"Harousseau","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.s.006_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199309148532","article-title":"Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia","volume":"9","author":"Estey","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2002.s.006_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.annonc.a057982","article-title":"Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia","volume":"2","author":"Pavlovsky","year":"1991","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.s.006_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/10428199809092692","article-title":"CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside\u2013a new salvage regimen for relapsed or refractory acute myelogenous leukemia","volume":"28","author":"Kornblau","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2002.s.006_bib12","first-page":"227","article-title":"Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia","volume":"32","author":"Harousseau","year":"1990","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.3816\/CLM.2002.s.006_bib13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.leu.2401066","article-title":"Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison","volume":"12","author":"Kern","year":"1998","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.s.006_bib14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.leu.2401474","volume":"13","author":"Thomas","year":"1999","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2002.s.006_bib15","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V83.8.2086.2086","article-title":"A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group","volume":"83","author":"Ohno","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.006_bib16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s002770050533","article-title":"Fludarabine, cytarabine, and GCSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation","volume":"78","author":"Ferrara","year":"1999","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2002.s.006_bib17","first-page":"238","volume":"71","author":"Saito","year":"2000","journal-title":"Int J Hematol"},{"key":"10.3816\/CLM.2002.s.006_bib18","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2037::AID-CNCR8>3.0.CO;2-K","article-title":"Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen","volume":"88","author":"Sternberg","year":"2000","journal-title":"Cancer"},{"key":"10.3816\/CLM.2002.s.006_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1995.13.1.11","article-title":"Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial","volume":"13","author":"Archimbaud","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.s.006_bib20","series-title":"Mylotarg\u2122 [package insert]","year":"2001"},{"key":"10.3816\/CLM.2002.s.006_bib21","first-page":"587a","article-title":"Steroids protect against infusion-related reactions to gentuzumab","volume":"98","author":"Lim","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.006_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2002.s.006_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2002.s.006_bib24","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/1097-0142(19831115)52:10<1803::AID-CNCR2820521007>3.0.CO;2-D","article-title":"Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia","volume":"52","author":"D'Cruz","year":"1983","journal-title":"Cancer"},{"key":"10.3816\/CLM.2002.s.006_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1445-5994.1987.tb00089.x","article-title":"Veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin","volume":"17","author":"Craft","year":"1987","journal-title":"Aust N Z J Med"},{"key":"10.3816\/CLM.2002.s.006_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-85-5-578","article-title":"Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases","volume":"85","author":"Griner","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2002.s.006_bib27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CLM.2002.s.006_bib28","first-page":"201b","article-title":"Non-fatal veno-occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin)","volume":"98","author":"Langston","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.006_bib29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction following gemtuzumab ozogamicin (Mylotarg\u2122)","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.006_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428199809059219","article-title":"Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy","volume":"31","author":"Richardson","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2002.s.006_bib31","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","article-title":"Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients","volume":"89","author":"Bearman","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.006_bib32","first-page":"721a","article-title":"An ursodiol and methylprednisone (MP) regimen does not reduce Mylotarg-associated hepatic veno-occlusive disease (VOD) in patients with acute myeloid leukemia (AML) not receiving stem cell transplantation (SCT)","volume":"98","author":"Giles","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.s.006_bib33","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.510290615","article-title":"Characterization of a reproducible rat model of hepatic veno-occlusive disease","volume":"29","author":"DeLeve","year":"1999","journal-title":"Hepatology"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511701567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511701567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:41:48Z","timestamp":1588920108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511701567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":32,"alternative-id":["S1526965511701567"],"URL":"https:\/\/doi.org\/10.3816\/clm.2002.s.006","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}